Compare Novartis AG (NVS) vs Sea Limited (SE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Sea Limited — how do they compare? Novartis AG trades at $142.86 (market cap $268.57B), while Sea Limited trades at $94.45 (market cap $56.89B). The key difference: Novartis AG is far larger — about 4.7× Sea Limited's market cap, and Novartis AG pays a 3.31% dividend while Sea Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Sea Limited for 102 Days on average.
| NVS | SE | |
|---|---|---|
Market Cap | $268.57B | $56.89B |
Volume | 1,532,573 | 5,359,457 |
Sector | Health | Consumer Cyclical |
52-Week High | $168.62 | $188.00 |
52-Week Low | $121.80 | $78.16 |
Typical Hold Time | 82 Days | 102 Days |
Enterprise Value | $309.89B | $51.92B |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% today, with mixed technical signals showing neutral momentum. The company demonstrates strong fundamentals with $56.67B revenue in 2025, 22.5% net margin, and consistent earnings beats in recent quarters. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though offset by clinical trial setbacks in ALS drug development and ongoing investor scrutiny of M&A strategy.
Outlook remains cautiously optimistic with analyst consensus target of $146 suggesting modest upside. Key opportunities include pipeline expansion through strategic partnerships, while risks involve clinical trial failures, M&A integration challenges, and patent cliff pressures. The stock presents a balanced risk-reward profile with strong profitability offset by pipeline execution concerns.
Sea Limited (SE) trades at $94.66, down 1.94% with bearish technical signals despite strong fundamentals. The company shows robust revenue growth from $16.8B in 2024 to $22.9B in 2025, with net income reaching $1.58B. Recent earnings show mixed results with Q1 and Q2 2026 beats but a Q4 2025 miss. Analyst consensus remains strongly bullish with a $153.67 price target, representing 62% upside potential from current levels.
The stock presents a compelling growth opportunity with improving profitability and strong cash flow generation, though technical weakness and insider selling create near-term headwinds. Key risks include execution challenges in e-commerce profitability and competitive pressures in Southeast Asian markets. The disconnect between strong fundamentals and bearish technicals suggests potential for recovery if earnings momentum continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Sea Limited
Sea Limited offers information technology services. The Company provides online personal computer and mobile digital content, e-commerce, and payment platforms. Sea serves customers worldwide.
Read more on SE →
